Advanced

Understanding and Modulating Immunity With Cell Reprogramming

Pires, Cristiana F. LU ; Rosa, Fábio F. LU ; Kurochkin, Ilia LU and Pereira, Carlos Filipe LU (2019) In Frontiers in Immunology 10.
Abstract

Cell reprogramming concepts have been classically developed in the fields of developmental and stem cell biology and are currently being explored for regenerative medicine, given its potential to generate desired cell types for replacement therapy. Cell fate can be experimentally reversed or modified by enforced expression of lineage specific transcription factors leading to pluripotency or attainment of another somatic cell type identity. The possibility to reprogram fibroblasts into induced dendritic cells (DC) competent for antigen presentation creates a paradigm shift for understanding and modulating the immune system with direct cell reprogramming. PU.1, IRF8, and BATF3 were identified as sufficient and necessary to impose DC fate... (More)

Cell reprogramming concepts have been classically developed in the fields of developmental and stem cell biology and are currently being explored for regenerative medicine, given its potential to generate desired cell types for replacement therapy. Cell fate can be experimentally reversed or modified by enforced expression of lineage specific transcription factors leading to pluripotency or attainment of another somatic cell type identity. The possibility to reprogram fibroblasts into induced dendritic cells (DC) competent for antigen presentation creates a paradigm shift for understanding and modulating the immune system with direct cell reprogramming. PU.1, IRF8, and BATF3 were identified as sufficient and necessary to impose DC fate in unrelated cell types, taking advantage of Clec9a, a C-type lectin receptor with restricted expression in conventional DC type 1. The identification of such minimal gene regulatory networks helps to elucidate the molecular mechanisms governing development and lineage heterogeneity along the hematopoietic hierarchy. Furthermore, the generation of patient-tailored reprogrammed immune cells provides new and exciting tools for the expanding field of cancer immunotherapy. Here, we summarize cell reprogramming concepts and experimental approaches, review current knowledge at the intersection of cell reprogramming with hematopoiesis, and propose how cell fate engineering can be merged to immunology, opening new opportunities to understand the immune system in health and disease.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antigen presentation, cancer immunotherapy, cell fate reprogramming, dendritic cell, hematopoiesis, regenerative medicine, transcription factor, transdifferentiation
in
Frontiers in Immunology
volume
10
article number
2809
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85077260284
ISSN
1664-3224
DOI
10.3389/fimmu.2019.02809
language
English
LU publication?
yes
id
8e54d75e-b074-40f5-9265-091d3718455f
date added to LUP
2020-01-10 13:13:28
date last changed
2020-01-16 04:09:14
@article{8e54d75e-b074-40f5-9265-091d3718455f,
  abstract     = {<p>Cell reprogramming concepts have been classically developed in the fields of developmental and stem cell biology and are currently being explored for regenerative medicine, given its potential to generate desired cell types for replacement therapy. Cell fate can be experimentally reversed or modified by enforced expression of lineage specific transcription factors leading to pluripotency or attainment of another somatic cell type identity. The possibility to reprogram fibroblasts into induced dendritic cells (DC) competent for antigen presentation creates a paradigm shift for understanding and modulating the immune system with direct cell reprogramming. PU.1, IRF8, and BATF3 were identified as sufficient and necessary to impose DC fate in unrelated cell types, taking advantage of Clec9a, a C-type lectin receptor with restricted expression in conventional DC type 1. The identification of such minimal gene regulatory networks helps to elucidate the molecular mechanisms governing development and lineage heterogeneity along the hematopoietic hierarchy. Furthermore, the generation of patient-tailored reprogrammed immune cells provides new and exciting tools for the expanding field of cancer immunotherapy. Here, we summarize cell reprogramming concepts and experimental approaches, review current knowledge at the intersection of cell reprogramming with hematopoiesis, and propose how cell fate engineering can be merged to immunology, opening new opportunities to understand the immune system in health and disease.</p>},
  author       = {Pires, Cristiana F. and Rosa, Fábio F. and Kurochkin, Ilia and Pereira, Carlos Filipe},
  issn         = {1664-3224},
  language     = {eng},
  month        = {12},
  publisher    = {Frontiers Media S. A.},
  series       = {Frontiers in Immunology},
  title        = {Understanding and Modulating Immunity With Cell Reprogramming},
  url          = {http://dx.doi.org/10.3389/fimmu.2019.02809},
  doi          = {10.3389/fimmu.2019.02809},
  volume       = {10},
  year         = {2019},
}